Company news
Nuvalent, Inc. (NASDAQ:NUVL) news
Nuvalent, Inc. news releases on 6ix. Latest, Sep 16, 2024: Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Press releases — page 2
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
September 15, 2024
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
September 13, 2024
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
September 12, 2024
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
September 8, 2024
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
August 7, 2024
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
July 21, 2024
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
July 15, 2024
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
July 10, 2024
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
May 28, 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
May 15, 2024
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
May 8, 2024
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
April 7, 2024
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
March 4, 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
February 26, 2024
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
February 11, 2024
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
January 7, 2024
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
November 13, 2023
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
October 31, 2023
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC
October 12, 2023
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile
October 3, 2023
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
September 17, 2023
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
September 4, 2023
Nuvalent to Participate in Upcoming September Investor Conferences
August 30, 2023
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
August 9, 2023
Nuvalent to Participate in Upcoming August Investor Conferences
July 31, 2023
Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
May 23, 2023
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
May 10, 2023
Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023
April 17, 2023
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
March 22, 2023
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 15, 2023
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
March 13, 2023
Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference
February 28, 2023
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 3, 2023
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520
December 12, 2022
Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results
November 9, 2022
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC
October 27, 2022
Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655
October 25, 2022
Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium
October 16, 2022
Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors
October 5, 2022
Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates
September 6, 2022
Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference
August 31, 2022
Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results
August 9, 2022
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
August 4, 2022
Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 2, 2022
Nuvalent Announces Leadership Promotions
July 19, 2022